Clinical Trial

Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma

Study acronym: PentixaFor
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 14, 2024 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.
Trial Details
NCT Number NCT06461182
Lead Sponsor Koo Foundation Sun Yat-Sen Cancer Center
Conditions Indolent B-Cell Non-Hodgkin Lymphoma
Enrollment 15 participants
Start Date 2024-04-29
Primary Completion 2026-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2024-06-14